Aimmune Therapeutics Inc (AIMT) Insider Douglas T. Sheehy Sells 1,648 Shares
Aimmune Therapeutics Inc (NASDAQ:AIMT) insider Douglas T. Sheehy sold 1,648 shares of the business’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $35.87, for a total transaction of $59,113.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Aimmune Therapeutics Inc (NASDAQ AIMT) traded down $0.03 during midday trading on Thursday, hitting $37.59. 265,783 shares of the stock were exchanged, compared to its average volume of 417,507. Aimmune Therapeutics Inc has a one year low of $15.97 and a one year high of $40.65. The firm has a market cap of $1,820.92, a P/E ratio of -15.98 and a beta of -0.82.
Aimmune Therapeutics (NASDAQ:AIMT) last posted its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.63) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.72) by $0.09. equities analysts expect that Aimmune Therapeutics Inc will post -2.51 earnings per share for the current fiscal year.
Several equities research analysts recently commented on the stock. Robert W. Baird assumed coverage on shares of Aimmune Therapeutics in a research report on Wednesday, December 20th. They issued an “outperform” rating and a $64.00 price objective on the stock. Piper Jaffray Companies set a $38.00 target price on shares of Aimmune Therapeutics and gave the company a “buy” rating in a research note on Saturday, October 21st. Credit Suisse Group boosted their target price on shares of Aimmune Therapeutics from $36.00 to $45.00 and gave the company an “outperform” rating in a research note on Monday, October 23rd. Zacks Investment Research downgraded shares of Aimmune Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, December 6th. Finally, Royal Bank of Canada initiated coverage on shares of Aimmune Therapeutics in a research note on Wednesday. They issued an “outperform” rating and a $55.00 target price for the company. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the stock. Aimmune Therapeutics has an average rating of “Buy” and a consensus target price of $57.25.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.watchlistnews.com/aimmune-therapeutics-inc-aimt-insider-douglas-t-sheehy-sells-1648-shares/1853045.html.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.